Aptose Reports Results for the First Quarter 2023
<!-- Name:DistributionId Value:8834370 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Aptose
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual…
<!-- Name:DistributionId Value:8804897 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual…
<!-- Name:DistributionId Value:8797102 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with…
<!-- Name:DistributionId Value:8738171 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across…
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients.…
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday,…
SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company…
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on…
SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated…
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company…
CORRECTION — Aptose Presents Highlights from Corporate Update and KOL Event
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June…
Aptose Presents Highlights from Corporate Update and KOL Event
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02,…